BioNTech SE (BNTX)
100.60
+1.85
(+1.87%)
USD |
NASDAQ |
May 31, 16:00
100.51
-0.09
(-0.09%)
After-Hours: 20:00
BioNTech Cash from Investing (TTM): -9.242B for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -9.242B |
December 31, 2023 | -7.529B |
September 30, 2023 | -4.801B |
June 30, 2023 | -3.561B |
March 31, 2023 | -1.150B |
December 31, 2022 | -37.23M |
September 30, 2022 | 6.505M |
June 30, 2022 | -377.16M |
March 31, 2022 | -313.20M |
Date | Value |
---|---|
December 31, 2021 | -669.80M |
September 30, 2021 | -662.42M |
June 30, 2021 | -208.18M |
March 31, 2021 | -183.02M |
December 31, 2020 | -165.37M |
September 30, 2020 | -64.50M |
June 30, 2020 | -62.21M |
March 31, 2020 | -65.19M |
December 31, 2019 | -86.43M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-9.242B
Minimum
Mar 2024
6.505M
Maximum
Sep 2022
-1.621B
Average
-260.69M
Median
Cash from Investing (TTM) Benchmarks
Pfizer Inc | -33.86B |
Moderna Inc | 2.313B |
GSK PLC | -1.678B |
NuCana PLC | 3.45M |
Autolus Therapeutics PLC | -7.897M |